Lymphangioma is a congenital malformed lymphatic tumor that rarely involves the tongue. In our clinic, a 10-year-old female presented with lymphangioma circumscriptum involving the right two-thirds of the tongue. We administered an intralesional combination injection of triamcinolone, bleomycin, and bevacizumab as a treatment. Almost complete remission after combination therapy was achieved without complications such as edema, swallowing difficulties or recurrence. Bevacizumab, an inhibitor of vascular endothelial growth factor, was effective for the treatment of lymphangioma of the tongue in this case. No recurrence was noted at the 1-year follow up.
INTRODUCTION
Lymphangioma is a congenital benign tumor of malformed lymphatic vessels [1, 2] . It is usually located in the head and neck. However, tongue lymphangioma has rarely been reported [3] [4] [5] [6] , and several such cases introduced surgical treatment or sclerotherapy [3] [4] [5] [6] [7] . However, complete excision of tongue lymphangioma is exceedingly difficult, especially for large lesions, owing to diffuse infiltration into tongue structures [5, 7] . Vital structural injuries can cause swallowing and speech problems. Sclerotherapy also has certain limitations. The posterior third or extensive involvement of the tongue might require airway protection with tracheostomy or sedation to prevent chewing the swollen tongue during treatment [8] . These patients require intensive care unit (ICU) admis-
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sion and a prolonged post-injection intubation period until the significant swelling subsides [8] . Intralesional steroid injection has also been used to treat tongue lymphangioma [4] ; however, curable treatment is not guaranteed with steroid injection only. Here, we present a case of lymphangioma circumscriptum with extensive tongue involvement that was successfully treated with a staged, combinational, intralesional injection with a minimum dose of steroid, bleomycin, and bevacizumab.
CASE REPORT
A 10-year-old girl presented with an approximately 70×35×20 mm reddish, verrucous, protruded lesion on the tongue (Fig. 1A) .
The lesion was detected 4 years ago and showed occasional bleeding. Mild swelling first appeared on the right side and gradually progressed to involve the left also. No specific treatment was administered. Examination revealed a yellowish and dark brownish thickening of the tongue. Multiple hemorrhagic, translucent vesicles were observed. Regional lymphadenopathy was absent. On palpation, the swelling was compressible and soft. Head/neck 55 www.e-acfs.org Jungil Hwang et al.
Combination therapy for tongue lymphangioma magnetic resonance imaging revealed a 50×35×25 mm ill-defined lesion in the right two-thirds of the tongue, posterior sublingual space, and genioglossus (Fig. 1B) . Incisional biopsy confirmed lymphangioma circumscriptum (Fig. 1C) .
Combination triamcinolone and bleomycin was directly injected in the tongue at monthly intervals. Table 1 shows the detailed injection ratios. Prophylactic intravenous antibiotics were administered before each intralesional injection. The initial triamcinolone concentration was greater than the bleomycin concentration to prevent post-injection swelling and airway obstruction because steroids inhibit the synthesis of multiple inflammatory proteins [9] .
After the first treatment, the lymphangioma decreased in size substantially ( Fig. 2A) . Each month, as the lymphangioma and tongue size decreased, the triamcinolone concentration was reduced and the bleomycin concentration was increased. Eight months after the first treatment, the lesion size stabilized ( Several possible approaches exist to treat lymphangiomas.
Complete tumor excision is the most desirable treatment. Incompletely removed lymphangiomas have a significantly higher recurrence rate than those that are completely removed [2] ; however, complete excision of tongue lymphangiomas is exceedingly difficult, especially with large lesions, owing to infiltration into vital structures. Operative complications including airway obstruction, nerve injury, wound infection, and scar formation are also significant. Vital structure injuries can lead to difficulty with swallowing or speech [5] . Operative morbidity and incomplete resection limit surgical excision of diffuse infiltrative tongue lymphangiomas.
Sclerosing agents such as bleomycin, OK-432, tetracycline, cyclophosphamide, and hypertonic saline are also commonly used to treat lymphangiomas [2, 6] . Literature abounds on the treatment of congenital lymphatic anomalies of the head and neck with bleomycin, which is an antiviral, antibacterial, and antitumor glycopeptide. Its main biochemical action is DNA strand scission with free radical release when the core is oxidized. It also has a sclerosing effect on the vessel endothelium [11] . Previous case reports introduced intralesional bleomycin injection as tongue lymphangioma treatment. However, the posterior third or extensive involvement might require airway protection with tracheostomy or sedation to prevent chewing the swollen tongue during treatment [8] . These patients require ICU admission and post-injection intubation until the mucosal swelling subsides [8] .
Therefore, treating large tongue lymphangioma with bleomycin has limitations.
Tongue lymphangioma treatment with intralesional steroids has also been reported. Intralesional steroids cause a significant increase in mast cell density, reduced transcription of cytokines, Vascular endothelial growth factor (VEGF) is a serum protein that promotes angiogenesis. VEGFs are significantly increased in proliferative lymphangioma vessels, which are almost absent in normal lymphoendothelial cells [12, 13] . Steroid therapy increases the mast cell number and cytokine concentration and decreases platelet-derived growth factor and interleukin-6. The therapy contributes to regression of the lymphatic malformation, but does not alter VEGF [9] . Bevacizumab, a recombinant humanized monoclonal antibody originally generated from mice immunized with recombinant human VEGF [14] , binds to VEGF and prevents VEGF binding to VEGF receptors [15] . Blockade of VEGF by bevacizumab is used as an effective treatment for capillary hemangioma and diabetic retinopathy [13, 16] and has been proved to be a treatment for lymphatic malformation [12, 17] . 
